Built on research from the world’s premier respiratory virus research hub in
Hong Kong
以全球首屈一指的呼吸道病毒研究中心的研究為基礎
State-of-art world class cell/organ culture laboratory for personalized respiratory tract platform
以世界最先進的細胞/器官培養實驗室研發個性化的呼吸道平台
World leading scientists in Influenza virus and Coronavirus research, as the No.1 institution in Asia ranks 3rd in COVID-19 and 4th in Influenza
匯聚亞洲排名第一院校、 COVID-19 研究中排名第三、流感研究中排名第四的科學家研究團隊
Services
服務
Risk assessment of newly emerging respiratory viruses
新發呼吸道病毒的風險評估
In vitro, in vivo and ex vivo assays specific for influenza viruses and coronaviruses in BSL2 and BSL3 labs.
在二級及三級生物安全實驗室以體外、體內和離體模型進行針對流感病毒和冠狀病毒的風險評估。
Anti-viral test
抗病毒測試
Our viral infected ex-vivo and organoid models for various respiratory viruses (influenza viruses and coronaviruses) can help to evaluate the efficacy of antiviral drugs / compounds.
我們提供各種呼吸道病毒（流感病毒和冠狀病毒）的病毒感染離體和類器官模型作為抗病毒藥物/化合物的安全及功效測試。
Assessment:
-
Drug induced cytotoxicity (CCK8)
-
Virus replication kinetics (TCID50, qPCR)
-
Pro-inflammatory cytokine profile (qPCR, flow cytometry)
-
Viral tropism (staining)
Platforms - for testing diagnostic, therapeutic, and antiviral products, and vaccines
技術平台 - 用於診斷治療、抗病毒藥物和疫苗研制
Respiratory Organoid Platform (ROP)
呼吸類器官平台 (ROP)
Personalised risk assessment platform for ROP 作為個性化風險評估平台:
-
Predicting the infectivity of emerging respiratory viruses and host response to the viruses
預測新發呼吸道病毒的傳染性和宿主對病毒的反應 -
Evaluating treatment responses 評估(藥物)治療效果
-
Developing personalized medicine 開發個性化醫療
Personalised platforms of human respiratory tract
人體呼吸道個性化平台
Characteristics of airway organoids 氣道類器官的特徵
